# Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

> **NCT00993486** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kiadis Pharma** · enrollment: 19 (actual)

## Conditions studied

- Hematologic Diseases
- Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)

## Key facts

- **NCT ID:** NCT00993486
- **Lead sponsor:** Kiadis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2008-10
- **Final completion:** 2013-04
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00993486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00993486, "Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00993486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*